Search

Your search keyword '"Cohen, Jeffrey"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Cohen, Jeffrey" Remove constraint Author: "Cohen, Jeffrey" Topic humans Remove constraint Topic: humans
44 results on '"Cohen, Jeffrey"'

Search Results

1. Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.

2. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.

3. Multiple sclerosis progression: time for a new mechanism-driven framework.

4. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

5. High risk of relapsed disease in patients with NK/T cell chronic active Epstein-Barr virus disease outside of Asia

6. Autoantibodies Against Proteins Previously Associated With Autoimmunity in Adult and Pediatric Patients With COVID-19 and Children With MIS-C

7. Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis

8. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials

9. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis

10. Artificial intelligence extension of the OSCAR‐IB criteria

11. Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients

12. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.

13. Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease

14. Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS

15. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

16. Childbearing and Family Leave Policies for Resident Physicians at Top Training Institutions.

17. Ultrarapid Measurement of Diagnostic Antibodies by Magnetic Capture of Immune Complexes.

18. Varicella zoster virus infection.

19. An ImmunoChip study of multiple sclerosis risk in African Americans.

20. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

22. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

23. Mental Health, Clinical Practice and COVID-19

24. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19

26. Early Adoption of Dupilumab in the Medicare Population in 2017

27. In Utero SARS-CoV-2 Infection

28. Editorial: EBV Infection and Human Primary Immune Deficiencies

29. Multiple sclerosis management during the COVID-19 pandemic

30. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS

31. Sequence variation of Epstein-Barr virus: viral types, geography, codon usage and diseases

32. Cell-based therapeutic strategies for multiple sclerosis

33. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

34. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

35. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

36. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial

37. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

38. Painful Pathways Induced by Toll-like Receptor Stimulation of Dorsal Root Ganglion Neurons

39. Increased Frequency of EBV-Specific Effector Memory CD8+ T Cells Correlates with Higher Viral Load in Rheumatoid Arthritis1

40. Strategies for Zoster Vaccination in Immunocompromised Patients

41. Ofatumumab versus Teriflunomide in Multiple Sclerosis

42. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

43. Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD

44. COVID-19 in people with multiple sclerosis: A global data sharing initiative

Catalog

Books, media, physical & digital resources